Anaferon for children, tablets 20 pcs

In preventive and therapeutic use the drug has immunomodulatory and antiviral effect. Experimental and clinical effectiveness against influenza viruses, herpes viruses (varicella, infectious mononucleosis), rotavirus is established.

The preparation decreases virus concentration in the affected tissues, affects the system of endogenous interferons and associated cytokines, induces formation of endogenous “early” interferons (IFN a/β) and gamma interferon (IFN γ).

Stimulates humoral and cellular immune response. Increases antibody production (including secretory IgA), activates Т-effectors and Т-helpers (Тх) functions, and normalizes their ratio. Increases the functional reserve of Tx and other cells involved in the immune response. It is an inducer of mixed Txl and Tx2-type immune response: it increases production of Txl cytokines (IFN γ, IL-2) and Tx2 (IL-4, 10), normalizes (modulates) the balance of Tx1/Tx2 activities. Increases the functional activity of phagocytes and natural killer cells (NK cells).

Indications

Prevention and treatment of influenza and acute respiratory viral infections (ARVI) in children aged 1 month to 18 years.
Treatment of infections caused by herpes viruses (infectious mononucleosis, chickenpox) as part of complex therapy in children aged 1 to 18 years.
Treatment of acute intestinal infection caused by rota- and caliciviruses as part of complex therapy in children aged 6 months to 18 years.

Pharmacological effect

Pharmacotherapeutic group: immunostimulants; other immunostimulants.

ATX code

L03AX.

Pharmacological action

When used prophylactically and therapeutically, the drug has an immunomodulatory and antiviral effect. Experimental and clinical effectiveness has been established against influenza A and B viruses, parainfluenza, rhinovirus, respiratory syncytial virus, adenovirus, seasonal strains of coronaviruses, metapneumovirus, bocavirus, herpes viruses (varicella, infectious mononucleosis), rotavirus, calicivirus. The drug reduces the concentration of the virus in the affected tissues, affects the system of endogenous interferons and associated cytokines, induces the formation of endogenous “early” interferons (IFN a/β) and interferon gamma (IFN γ).

Stimulates the humoral and cellular immune response. Increases the production of antibodies (including secretory IgA), activates functions
T-effectors, T-helpers (Tx), normalizes their ratio. Increases the functional reserve of Tx and other cells involved in the immune response. It is an inducer of a mixed Txl and Th2 type of immune response: it increases the production of Txl (IFN γ, IL-2) and Th2 (IL-4, 10) cytokines, normalizes (modulates) the balance of Th1/Th2 activities. Increases the functional activity of phagocytes and natural killer cells
(NK cells).

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active substance of the drug Anaferon® for children in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Special instructions

The drug contains lactose monohydrate, and therefore is not recommended for use in patients with congenital galactosemia, glucose malabsorption syndrome, or congenital lactase deficiency.

Impact on the ability to drive vehicles and machinery
There are no data on the effect on the ability to drive vehicles and operate machinery.

Composition

1 tablet contains:

Active ingredient:

Affinity purified antibodies to human interferon gamma – 5,000 EMD*.

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* EMD – units of modifying action.

Pregnancy

The safety of using Anaferon® for children in pregnant women and during lactation has not been studied. If it is necessary to take the drug, the risk/benefit ratio should be taken into account.

Contraindications

Increased individual sensitivity to the components of the drug.
Children up to 1 month of age – for the prevention and treatment of influenza and other acute respiratory viral infections.
Children under 1 year of age – for the treatment of infections caused by herpes viruses in children (chickenpox, infectious mononucleosis).
Children up to 6 months of age – for the treatment of acute intestinal infection caused by rota and caliciviruses.
Lactase deficiency, hereditary galactose intolerance, glucose-galactose malabsorption.

Side Effects

Allergic reactions and manifestations of increased individual sensitivity to the components of the drug are possible. If you experience any unwanted reactions listed in the instructions or they get worse, or you notice any other unwanted reactions not listed in the instructions, tell your doctor.

Interaction

No cases of incompatibility with other drugs have been identified to date.
If necessary, the drug can be combined with other antiviral, antibacterial and symptomatic agents.

Overdose

In case of overdose, dyspepsia may occur due to the excipients included in the drug. Treatment is symptomatic.

Short product description

Anaferon for children is an original antiviral drug, specially created for the treatment and prevention of ARVI and influenza in children from 1 month of age. It has a wide spectrum of antiviral activity, including influenza. Has a favorable safety profile. If necessary, can be combined with other antiviral, antibacterial and symptomatic agents.

Storage conditions

At a temperature not exceeding 25 °C.
Keep out of the reach of children.
During the period of use of the drug, store the blister pack in a cardboard box provided by the manufacturer.

Shelf life

3 years. Do not use after expiration date.

Manufacturer

Materia Medica Holding, Russia